Resources

Select from the drop-down menu below to read the most up-to-date news about pelareorep.

November 8, 2022 | Poster
The oncolytic virus pelareorep in combination with immune checkpoint inhibitor activates T-cell functioning in early breast cancer patients – immunophenotype results from AWARE-1 study
González-Navarro, E.A et al, Previously presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting; November 8-12, 2022
June 29, 2022 | Poster
GOBLET: A phase 1/2 multiple indication signal finding and biomarker study in advanced gastrointestinal cancers treated with pelareorepand atezolizumab –safety and preliminary response results
Collienne, Maike et al, Previously presented at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022; June 29 – July 2, 2022
May 3, 2022 | Poster
The oncolytic virus pelareorep primes the tumor microenvironment for checkpoint blockade therapy in early breast cancer patients – Results from AWARE-1 study
Gavilá, Joaquín et al, Previously presented at the European Society for Medical Oncology Breast Cancer 2022 Meeting; May 3-5, 2022
April 8, 2022 | Poster
Single Cell Analysis Shows That Reovirus Immune Priming Changes the Tumor Immune Micro Environment in Multiple Myeloma
Olea, Julian et al, Previously presented at the American Association for Cancer Research Annual Meeting 2022; April 8-13, 2022
April 8, 2022 | Poster
Combination of reovirus (Pelareorep) and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant chemotherapy (temozolomide) for patients with glioblastoma multiforme (GBM): Long term follow up results of the ReoGliophase Ibtrial
Short, Susan, Previously presented at the American Association for Cancer Research Annual Meeting 2022; April 8-13, 2022
January 20, 2022 | Poster
GOBLET: A phase 1 / 2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic gastrointestinal cancers exploring treatment combinations with pelareorep and atezolizumab
Arnold, Dirk et al, Previously presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 20-22, 2022
December 1, 2021 | Poster
The Clinical Oncolytic Reovirus Formulation Reolysin Synergistically Augments the Anti-Leukemic Activity of Azacitidine
Schwartz, Rayna et al, Previously presented at the 63rd ASH® Annual Meeting and Exposition
December 1, 2021 | Poster
IRENE study: Phase 2 study of Retifanlimab and the oncolytic virus pelareorep in metastatic triple negative breast cancer
George, Mridula et al, Previously presented at the 2021 San Antonio Breast Cancer Symposium®; San Antonio, TX, USA

Expanded Access

Oncolytics believes that participating in clinical trials is the best way for patients to access pelareorep. We are not currently able to fulfill expanded access requests at this time.

Information on many of Oncolytics clinical trials can be found at Home – ClinicalTrials.gov. If a treating physician would like additional information, the physician should directly contact Oncolytics at info@oncolytics.ca.

Information on many of Oncolytics clinical trials can be found at Home – ClinicalTrials.gov. If a treating doctor would like additional information, the doctor should formally contact Oncolytics at info@oncolytics.ca.

Contact Us

For questions regarding our science, partnership opportunities, or other inquiries, we encourage you to reach out.

Get in touch